5-HT obesity medication efficacy via POMC activation is maintained during aging

Peer reviewedPublisher PD

Pooled analysis of WHO Surgical Safety Checklist use and mortality after emergency laparotomy

Background The World Health Organization (WHO) Surgical Safety Checklist has fostered safe practice for 10 years, yet its place in emergency surgery has not been assessed on a global scale. The aim of this study was to evaluate reported checklist use in emergency settings and examine the relationship with perioperative mortality in patients who had emergency laparotomy. Methods In two multinational cohort studies, adults undergoing emergency laparotomy were compared with those having elective gastrointestinal surgery. Relationships between reported checklist use and mortality were determined using multivariable logistic regression and bootstrapped simulation. Results Of 12 296 patients included from 76 countries, 4843 underwent emergency laparotomy. After adjusting for patient and disease factors, checklist use before emergency laparotomy was more common in countries with a high Human Development Index (HDI) (2455 of 2741, 89.6 per cent) compared with that in countries with a middle (753 of 1242, 60.6 per cent; odds ratio (OR) 0.17, 95 per cent c.i. 0.14 to 0.21, P <0001) or low (363 of 860, 422 per cent; OR 008, 007 to 010, P <0.001) HDI. Checklist use was less common in elective surgery than for emergency laparotomy in high-HDI countries (risk difference -94 (95 per cent c.i. -11.9 to -6.9) per cent; P <0001), but the relationship was reversed in low-HDI countries (+121 (+7.0 to +173) per cent; P <0001). In multivariable models, checklist use was associated with a lower 30-day perioperative mortality (OR 0.60, 0.50 to 073; P <0.001). The greatest absolute benefit was seen for emergency surgery in low- and middle-HDI countries. Conclusion Checklist use in emergency laparotomy was associated with a significantly lower perioperative mortality rate. Checklist use in low-HDI countries was half that in high-HDI countries.Peer reviewe

Global variation in anastomosis and end colostomy formation following left-sided colorectal resection

Background End colostomy rates following colorectal resection vary across institutions in high-income settings, being influenced by patient, disease, surgeon and system factors. This study aimed to assess global variation in end colostomy rates after left-sided colorectal resection. Methods This study comprised an analysis of GlobalSurg-1 and -2 international, prospective, observational cohort studies (2014, 2016), including consecutive adult patients undergoing elective or emergency left-sided colorectal resection within discrete 2-week windows. Countries were grouped into high-, middle- and low-income tertiles according to the United Nations Human Development Index (HDI). Factors associated with colostomy formation versus primary anastomosis were explored using a multilevel, multivariable logistic regression model. Results In total, 1635 patients from 242 hospitals in 57 countries undergoing left-sided colorectal resection were included: 113 (6·9 per cent) from low-HDI, 254 (15·5 per cent) from middle-HDI and 1268 (77·6 per cent) from high-HDI countries. There was a higher proportion of patients with perforated disease (57·5, 40·9 and 35·4 per cent; P < 0·001) and subsequent use of end colostomy (52·2, 24·8 and 18·9 per cent; P < 0·001) in low- compared with middle- and high-HDI settings. The association with colostomy use in low-HDI settings persisted (odds ratio (OR) 3·20, 95 per cent c.i. 1·35 to 7·57; P = 0·008) after risk adjustment for malignant disease (OR 2·34, 1·65 to 3·32; P < 0·001), emergency surgery (OR 4·08, 2·73 to 6·10; P < 0·001), time to operation at least 48 h (OR 1·99, 1·28 to 3·09; P = 0·002) and disease perforation (OR 4·00, 2·81 to 5·69; P < 0·001). Conclusion Global differences existed in the proportion of patients receiving end stomas after left-sided colorectal resection based on income, which went beyond case mix alone

The metabolic effects and therapeutic utility of novel GLP-1/Glucagon receptor co-agonists in type 2 diabetes

Type 2 Diabetes Mellitus is a metabolic disorder characterised by persistent hyperglycaemia. The global rise in obesity has fuelled an increase in the prevalence of diabetes and necessitates more effective treatments. Glucagon-like peptide-1 (GLP-1) analogues are one of the most efficacious therapeutics currently available, and simultaneously stimulate insulin secretion and increase insulin sensitivity through weight loss. Consequently, GLP-1 analogues are particularly useful for diabetic patients who are overweight or obese. It has been hypothesised that the tolerability and therapeutic efficacy of GLP-1 analogues could be enhanced by combining GLP-1 with a second insulinotropic hormone. Based on the well-established beneficial metabolic effects of oxyntomodulin, a naturally occurring GLP-1 and glucagon receptor co-agonist, glucagon has been proposed as a co-adjunct for GLP-1. While multiple groups have demonstrated the superior weight loss efficacy of GLP-1 and glucagon receptor co-agonists versus GLP-1 analogues, the insulinotropic effects of co-agonists remain undetermined. This project involved the development of novel GLP-1 and glucagon receptor co-agonists based on the sequence of oxyntomodulin, with targeted sequence modifications to confer longer plasma half lives and greater potency. To determine the direct beta cell effects of co-agonists, insulin secretion assays were performed in vitro using INS-1 832/3, MIN6B1 and EndoC-βH1 beta cells. In comparison to GLP-1 analogues, my co-agonists augmented insulin release in vitro. These insulinotropic effects were preserved in vivo in a high-fat, high-sucrose fed mouse model of type 2 diabetes, where the co-agonists led to greater insulinotropic responses than GLP-1 analogues acutely. On chronic administration, co-agonists did not impair glycaemic control despite their considerable glucagon receptor activity. In addition, co-agonists induced profound weight loss chronically, which was attributed to both food intake reduction through the GLP-1 receptor and energy expenditure effects through glucagon receptor activation. Paradoxically, the weight loss did not lead to improvements in glucose tolerance. The in vitro insulinotropic effects were associated with a signalling bias against β arrestin recruitment at the GLP-1R and could be due to reduced receptor trafficking and internalisation. However, the in vivo characteristics show no correlation to bias, and weight loss was instead found to be positively associated with relative glucagon receptor activity of the co-agonists. These findings highlight the potential of co-agonists as a safe therapy for weight loss in patients with diabetes and could inform the design of more potent insulinotropic compounds for therapeutic use in type 2 diabetes.Open Acces

Global variation in anastomosis and end colostomy formation following left-sided colorectal resection

Background: End colostomy rates following colorectal resection vary across institutions in high-income settings, being influenced by patient, disease, surgeon and system factors. This study aimed to assess global variation in end colostomy rates after left-sided colorectal resection. Methods: This study comprised an analysis of GlobalSurg-1 and-2 international, prospective, observational cohort studies (2014, 2016), including consecutive adult patients undergoing elective or emergency left-sided colorectal resection within discrete 2-week windows. Countries were grouped into high-, middle-and low-income tertiles according to the United Nations Human Development Index (HDI). Factors associated with colostomy formation versus primary anastomosis were explored using a multilevel, multivariable logistic regression model. Results: In total, 1635 patients from 242 hospitals in 57 countries undergoing left-sided colorectal resection were included: 113 (6·9 per cent) from low-HDI, 254 (15·5 per cent) from middle-HDI and 1268 (77·6 percent) from high-HDI countries. There was a higher proportion of patients with perforated disease (57·5, 40·9 and 35·4 per cent; P &lt; 0·001) and subsequent use of end colostomy (52·2, 24·8 and 18·9 per cent; P &lt; 0·001) in low-compared with middle-and high-HDI settings. The association with colostomy use in low-HDI settings persisted (odds ratio (OR) 3·20, 95 per cent c.i. 1·35 to 7·57; P = 0·008) after risk adjustment for malignant disease (OR 2·34, 1·65 to 3·32; P &lt; 0·001), emergency surgery (OR 4·08, 2·73 to 6·10; P &lt; 0·001), time to operation at least 48 h (OR 1·99, 1·28 to 3·09; P = 0·002) and disease perforation (OR 4·00, 2·81 to 5·69; P &lt; 0·001). Conclusion: Global differences existed in the proportion of patients receiving end stomas after left-sided colorectal resection based on income, which went beyond case mix alone